# Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.

Study · id `cardio:ct-nct07288749` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07288749](<https://clinicaltrials.gov/study/NCT07288749>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07288749

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1484 participants.

## Technical summary

Registry record NCT07288749. Randomized; quadruple masking; primary purpose treatment. Start 2026-01-01 (anticipated); primary completion 2030-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1484 participants (planned count; ClinicalTrials.gov record NCT07288749, source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)
- Planned start: 2026-01-01 (anticipated) (ClinicalTrials.gov record NCT07288749, source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)
- Primary completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT07288749, source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)
- Completion: 2031-12-31 (anticipated) (ClinicalTrials.gov record NCT07288749, source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07288749, source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07288749-2025-12-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus and Chronic Heart Failure With Reduced Ejection Fraction.
- Acronym: GLID-HF
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Chronic Heart Failure (CHF)
- Intervention (Drug): Glimepiride (oral)
- Intervention (Drug): Placebo
- Lead sponsor: Tongji Hospital
- Lead sponsor class: OTHER
- Collaborator: Shanghai Zhongshan Hospital
- Collaborator class: OTHER
- Collaborator: Nanjing Medical University
- Collaborator class: OTHER
- Collaborator: Second Xiangya Hospital of Central South University
- Collaborator class: OTHER
- Collaborator: Huaxi Hospital
- Collaborator class: OTHER
- Collaborator: Zhongnan Hospital
- Collaborator class: OTHER
- Collaborator: Xiangya Hospital
- Collaborator class: OTHER
- Collaborator: Beijing Anzhen Hospital
- Collaborator class: OTHER
- Collaborator: The First Affiliated Hospital of Air Force Medical University
- Collaborator class: OTHER
- Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator class: OTHER
- Collaborator: The First Affiliated Hospital of Zhengzhou University
- Collaborator class: OTHER
- Collaborator: First Affiliated Hospital of Xinjiang Medical University
- Collaborator class: OTHER
- Collaborator: Anhui Provincial Hospital
- Collaborator class: OTHER\_GOV
- Collaborator: Southwest Medical University
- Collaborator class: OTHER
- Collaborator: First Hospital of China Medical University
- Collaborator class: OTHER
- Collaborator: Wuhan Central Hospital
- Collaborator class: OTHER
- Collaborator: Tianjin Medical University
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 13 registry organizations

## Provenance

Content hash: d88b43f5124c7ba633ec9d03276becc04b52094bc9fbbe53df64dd516f39c344
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
